Nedim Turan1, Mustafa Benekli2, Faysal Dane3, Olcun Umit Unal4, Hasan Volkan Kara5, Dogan Koca6, Ozlem Balvan7, Tulay Eren8, Didem Tastekin9, Kaan Helvaci10, Veli Berk11, Umut Demirci10, Selcuk Cemil Ozturk12, Erkan Dogan6, Bulent Cetin6, Mehmet Kucukoner13, Onder Tonyali14, Gulnihal Tufan15, Ilhan Oztop4, Mahmut Gumus7, Ugur Coskun2, Aytug Uner2, Ahmet Ozet2, Suleyman Buyukberber2. 1. Department of Medical Oncology, Malatya State Hospital Malatya, Turkey. 2. Department of Medical Oncology, Gazi University Faculty of Medicine Ankara, Turkey. 3. Department of Medical Oncology, Marmara University Faculty of Medicine Istanbul, Turkey. 4. Department of Medical Oncology, Dokuz Eylül University Faculty of Medicine Izmir, Turkey. 5. Department of Thoracic Surgery, Marmara University Faculty of Medicine Istanbul, Turkey. 6. Department of Medical Oncology, Regional Training and Research Hospital Van, Turkey. 7. Department of Medical Oncology, Dr Lutfi Kirdar Kartal Education and Research Hospital Istanbul, Turkey. 8. Department of Medical Oncology, Numune Education and Research Hospital Ankara, Turkey. 9. Department of Medical Oncology, Necmettin Erbakan University Faculty of Medicine Konya, Turkey. 10. Department of Medical Oncology, Dr Abdurrahman Yurtaslan Education and Research Hospital Ankara, Turkey. 11. Department of Medical Oncology, Erciyes University Faculty of Medicine Kayseri, Turkey. 12. Department of Medical Oncology, Adıyaman University Education and Research Hospital Adıyaman, Turkey. 13. Department of Medical Oncology, Dicle University Faculty of Medicine Diyarbakir, Turkey. 14. Department of Medical Oncology, Antakya State Hospital Hatay, Turkey. 15. Department of Medical Oncology, Rize Education and Research Hospital Rize, Turkey.
Abstract
INTRODUCTION: We investigated the impact of modern chemotherapy regimens and bevacizumab following pulmonary metastasectomy (PM) from metastatic colorectal cancer (CRC). METHODS: A total of 122 consecutive patients who were curatively resected for pulmonary metastases of CRC in twelve oncology centers were retrospectively analysed between January 2000 and April 2012. RESULTS: Of 122 patients, 14 did not receive any treatment following PM. The remaining 108 patients received fluoropyrimidine-based (n = 12), irinotecan-based (n = 56) and oxaliplatin-based (n = 40) chemotherapy combinations. Among these, 52 patients received bevacizumab (BEV) while 56 did not (NoBEV). Median recurrence-free survival (RFS) was 17 months and median overall survival (OS) has not been reached at a median follow-up of 25 months after PM. Three and five-year OS rates were 66% and 53%, respectively. RFS and OS were similar, irrespective of the chemotherapy regimen or BEV use. Positive pulmonary margin, KRAS mutation status, and previous liver metastasectomy were negative independent prognostic factors for RFS, while pathologically confirmed thoracic lymph node involvement was the only negative independent prognostic for OS in multivariate analysis. CONCLUSIONS: No significant RFS or OS difference was observed in respect to chemotherapy regimens with or without BEV in patients with pulmonary metastases of CRC following curative resection.
INTRODUCTION: We investigated the impact of modern chemotherapy regimens and bevacizumab following pulmonary metastasectomy (PM) from metastatic colorectal cancer (CRC). METHODS: A total of 122 consecutive patients who were curatively resected for pulmonary metastases of CRC in twelve oncology centers were retrospectively analysed between January 2000 and April 2012. RESULTS: Of 122 patients, 14 did not receive any treatment following PM. The remaining 108 patients received fluoropyrimidine-based (n = 12), irinotecan-based (n = 56) and oxaliplatin-based (n = 40) chemotherapy combinations. Among these, 52 patients received bevacizumab (BEV) while 56 did not (NoBEV). Median recurrence-free survival (RFS) was 17 months and median overall survival (OS) has not been reached at a median follow-up of 25 months after PM. Three and five-year OS rates were 66% and 53%, respectively. RFS and OS were similar, irrespective of the chemotherapy regimen or BEV use. Positive pulmonary margin, KRAS mutation status, and previous liver metastasectomy were negative independent prognostic factors for RFS, while pathologically confirmed thoracic lymph node involvement was the only negative independent prognostic for OS in multivariate analysis. CONCLUSIONS: No significant RFS or OS difference was observed in respect to chemotherapy regimens with or without BEV in patients with pulmonary metastases of CRC following curative resection.
Authors: U Pastorino; M Buyse; G Friedel; R J Ginsberg; P Girard; P Goldstraw; M Johnston; P McCormack; H Pass; J B Putnam Journal: J Thorac Cardiovasc Surg Date: 1997-01 Impact factor: 5.209
Authors: Chang Hyun Kim; Jung Wook Huh; Hun Jin Kim; Sang Woo Lim; Sang Yun Song; Hyeong Rok Kim; Kook Joo Na; Young Jin Kim Journal: Dis Colon Rectum Date: 2012-04 Impact factor: 4.585
Authors: Timothy J Price; Jennifer E Hardingham; Chee K Lee; Andrew Weickhardt; Amanda R Townsend; Joseph W Wrin; Ann Chua; Aravind Shivasami; Michelle M Cummins; Carmel Murone; Niall C Tebbutt Journal: J Clin Oncol Date: 2011-06-06 Impact factor: 44.544
Authors: Aimery de Gramont; Eric Van Cutsem; Hans-Joachim Schmoll; Josep Tabernero; Stephen Clarke; Malcolm J Moore; David Cunningham; Thomas H Cartwright; J Randolph Hecht; Fernando Rivera; Seock-Ah Im; György Bodoky; Ramon Salazar; Frédérique Maindrault-Goebel; Einat Shacham-Shmueli; Emilio Bajetta; Martina Makrutzki; Aijing Shang; Thierry André; Paulo M Hoff Journal: Lancet Oncol Date: 2012-11-16 Impact factor: 41.316
Authors: S Salah; K Watanabe; S Welter; J S Park; J W Park; J Zabaleta; F Ardissone; J Kim; M Riquet; K Nojiri; M Gisabella; S Y Kim; K Tanaka; B Al-Haj Ali Journal: Ann Oncol Date: 2012-04-29 Impact factor: 32.976
Authors: Richard M Goldberg; Daniel J Sargent; Roscoe F Morton; Charles S Fuchs; Ramesh K Ramanathan; Stephen K Williamson; Brian P Findlay; Henry C Pitot; Steven Alberts Journal: J Clin Oncol Date: 2006-07-20 Impact factor: 44.544
Authors: Wânia Cristina da Silva; Vânia Eloisa de Araujo; Ellias Magalhães E Abreu Lima; Jessica Barreto Ribeiro Dos Santos; Michael Ruberson Ribeiro da Silva; Paulo Henrique Ribeiro Fernandes Almeida; Francisco de Assis Acurcio; Brian Godman; Amanj Kurdi; Mariângela Leal Cherchiglia; Eli Iola Gurgel Andrade Journal: BioDrugs Date: 2018-12 Impact factor: 5.807